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Prostate-speciﬁc antigen (PSA) is well known as a speciﬁc tumor marker for prostate cancer, but carci-
noembryonic antigen (CEA)- and carbohydrate antigen 19-9 (CA19-9)-elevating adenocarcinomas orig-
inating in the prostate gland are rare. We report a case of metastatic adenocarcinoma of the prostate
gland with a high serum level of CEA and CA19-9 in a 78-year-old man in whom prostate cancer
(T3N1M1) had been diagnosed 2 years ago and who was treated with androgen deprivation therapy. He
visited the emergency department because of a loss of appetite and abdominal pain. The serum CEA and
CA19-9 levels were increased to 218.9 ng/mL (normal, <5 ng/mL) and 212 ng/mL (normal, <27 ng/mL),
respectively. The serum PSA level was slightly elevated (4.41 ng/mL). Computed tomography demon-
strated multiple liver metastases, para-aortic lymph node enlargement, and lung metastases. A liver
biopsy was performed and the specimen showed high-grade adenocarcinomawith focal positive staining
for PSA. Despite chemotherapy with docetaxel, the patient died 3 months after treatment. Based on this
case and a review of the literature, an aggressive variant of prostatic carcinomawith a high serum level of
CEA and CA19-9 and a low PSA level was shown to progress rapidly with a poor prognosis.
Copyright  2013, Taiwan Urological Association. Published by Elsevier Taiwan LLC.Open access under CC BY-NC-ND license.1. Introduction
The most common speciﬁc tumor marker for prostatic carci-
noma is prostate-speciﬁc antigen (PSA). The PSA level is the most
valuable tool for monitoring disease status and treatment response,
especially in patients with advanced metastatic prostate cancer.1
Carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9
(CA 19-9) have been used primarily as tumor markers in gastroin-
testinal carcinomas. CEA- and CA19-9-elevating carcinomas origi-
nating in the prostate gland are rare. We report a case of metastatic
prostate cancer with high serum level of CEA and CA19-9.
2. Case report
Prostate cancer was diagnosed by ultrasound-guided biopsy in
June 2008 in a 78-year-old man with a history of coronary
artery disease, diabetes mellitus, hypertension, and lower urinary
tract symptoms. The serum PSA level was elevated (64.96 ng/mL)tment of Surgery, Shin-Kong
in District, Taipei 111, Taiwan.
ang).
ciation. Published by Elsevier Taiwat the time of diagnosis. Histologic examination revealed an
adenocarcinoma of the prostate with a Gleason score of 9 (4þ 5).
Computed tomography (CT) and whole-body bone scans were
subsequently performed and the diagnosis of clinical stage
T3N1M1 prostatic adenocarcinoma was made. The patient under-
went hormonal ablative therapy with cyproterone acetate and a
luteinizing hormone releasing hormone analog.
Serial serum PSA levels were determined. The PSA level
decreased to 4.46 ng/mL 12 months after androgen deprivation
therapy (ADT). Pelvic CT and whole-body bone scanning were
performed and showed regression of pelvic lymph node and bony
metastases (Fig. 1). The nadir PSA was 1.04 ng/mL 16 months after
hormonal therapy, and this level persisted (Fig. 2).
Thirty months after hormonal therapy, the patient presented
with abdominal pain, loss of appetite, and weakness in both legs.
An abdominal echogram revealed multiple liver metastases. The
tumor markers of CEA, alpha-fetoprotein (AFP), CA19-9, lactate
dehydrogenase (LDH), and PSA were determined. The serum CEA
and CA19-9 levels were increased to 218.9 ng/mL (normal, <5 ng/
mL) and 212 ng/mL (normal, <27 ng/mL), respectively; the serum
PSA level was slightly elevated (4.44 ng/mL), the AFP and LDH were
4.56 ng/mL and 68 ng/mL, respectively. CT of the chest, abdomen,an LLC. Open access under CC BY-NC-ND license.
Fig. 1. Whole-body bone scans showing (A) multiple metastases and (B) regression of bony metastases after androgen deprivation therapy.
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lymph node enlargement, and lung metastases. No evidence of
another primary tumor was evident on CT scan (Fig. 3).
The patient complained of abdominal pain and had an elevation
of tumor markers for gastrointestinal cancer with liver metastases.
A second malignancy was suspected and the diagnosis was
reevaluated. A panendoscopy was performed, but no evidence of a
tumor was seen in the stomach or colorectum. A liver biopsy was
arranged and demonstrated high-grade adenocarcinoma with
positive immunohistochemical staining for PSA and cytokeratin in
focal tumor cells, but negative immunohistochemical staining for
CEA (Fig. 4).
The diagnosis of metastases of prostatic carcinoma was
conﬁrmed. A chemotherapy regimen with docetaxel (75 mg/m2)
and prednisone was initiated; however, the patient’s general con-
dition progressively declined. The serum level of CEA and CA19-9
was increased to 267.5 ng/mL and 256.0 ng/mL, respectively, in 1
month after initiating chemotherapy. Despite docetaxel-basedFig. 2. Clinical course of the patient. The serum prostate-speciﬁc antigen (PSA) level
declined after androgen deprivation therapy. The nadir PSA was 1.04 ng/mL 16 months
after hormonal therapy (arrow).chemotherapy, the patient died of rapid tumor extension 3
months after diagnosis.
3. Discussion
Prostate cancer is the most common cancer and the second
leading cause of cancer deaths in men.2 The serum PSA levels and
pathologic grading are currently used for predicting the activity and
tumor size of prostate cancer.1 Prostate cancer is usually an
androgen-dependent tumor, and sensitive to ADT in patients with
advanced metastatic prostate cancer. The PSA level is the most
sensitive tool for monitoring disease status and treatment
response. Based on a rising PSA level, recurrent prostate cancer is
diagnosed after antihormonal therapy; however, progression of
prostate cancer can sometimes occur despite a low serum PSA level.
In 2001, Yamamoto et al3 reported eight patients with progression
of prostate cancer (stage M1) in the presence of an undetectable or
low serum PSA. Most of the patients had rapid cancer progression
and a poor prognosis compared with typical M1 prostate cancer.
ADT was ineffective in these cases, and therefore Yamamoto et al3
recommended initial therapy with combination radiotherapy and
systemic chemotherapy. Leibovici et al4 reported that patients with
metastatic prostate cancer and a low serum PSA account for <1% of
all patients with metastatic prostate cancer. Limited data are
available to analyze the basis for recurrent prostate cancer with a
low serum PSA. Oefelein et al5 reported that patients with prostate
cancer progression and undetectable serum PSA levels after radical
prostatectomy had rapid progression.
Other investigators have reported that serum CEA, CA19-9, and
CA15-3 levels are elevated in patients with metastatic prostate
cancer and normal serum PSA levels.6,7 Moreover, it was reported
that these progressive prostate cancers were characterized by
visceral metastases, a high proportion of lytic bony metastatic
disease, poor differentiation on histologic examination, and sensi-
tivity to cisplatin-based chemotherapy. In the reports of Sella et al6
and Nishio et al,7 the immunohistochemical staining for CEA were
all negative, similar to the result of our case. The common features
of these cases were a high serum level of CEA and CA-19-9 and low
serum PSA. The metastatic prostate cancer was conﬁrmed by bi-
opsy demonstrated with positive immunohistochemical staining
Fig. 3. Prostate cancer with multiple metastases in the patient. Abdominal and pelvic computed tomography showing multiple hepatic metastases (A) and para-aortic lymph node
metastases (B).
Fig. 4. (A) Histologic examination of the liver biopsy revealed high-grade adenocarcinoma. Irregular gland size and gland fusion are shown (hematoxylin and eosin, 400). (B)
Positive immunohistochemical staining (arrows) for prostate-speciﬁc antigen (PSA) in focal tumor cells (PSA stain, 400). (C) Negative immunohistochemical staining for carci-
noembryonic antigen (CEA stain, 400).
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different carcinomas, but it is not known whether CEA and CA19-9
are useful in prostate cancer. CEA is a membrane-associated
glycoprotein that is expressed mainly in the gut epithelium and is
upregulated in tumor cells, especially in gastrointestinal carcinoma
and breast cancer. Using immunohistochemical studies, Ghaziza-
deh et al8 found that normal prostate tissue is able to produce CEA,
which is signiﬁcantly upregulated in prostate carcinoma. Feuer
et al9 also documented that CEA is elevated in patients with
androgen-independent prostate cancer, but CEA had no prognostic
effect on the length of survival. CA19-9 is a tumor marker for
gastrointestinal cancer, but is also found in the normal prostate and
seminal plasma.10 Until now, no data have been available regarding
the role of CA19-9 serum levels in patients with prostate cancer.
The case presented herein had a high-grade Gleason score, a low
PSA level, visceral metastases, and elevated levels of tumormarkers
(CA19-9 and CEA). Comparedwith previous reports, the response to
docetaxel-based chemotherapy was poor and the cancer pro-
gressed rapidly.
In conclusion, prostate cancer may progress in spite of a low
serum PSA level. CEA and CA19-9 might not be prostate cancer-
speciﬁc; thus, the role in patients with prostate cancer is uncer-
tain. Based on this case and previous reports, an aggressive variant
of prostatic carcinoma producing CEA and CA19-9 and a low PSA
level portends rapid progression and a poor prognosis.
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